摘要
Background and Aims:Glecaprevir/pibrentasvir is a pangenotypic regimen recently approved for the treatment of chronic hepatitis C virus(HCV)infection.The objective of the present review was to summarize the findings from clinical trials to understand how patient-related factors influence glecaprevir/pibrentasvir efficacy(sustained virologic response rates at 12 weeks’after treatment[referred to as SVR12])and safety.Methods:Data from 21 phase III clinical trials were analyzed.Results:The integrated efficacy analysis included 4,817 patients.Findings showed 97.5%of all included patients with chronic HCV achieved SVR12 in the intention-to-treat population.SVR12 rate was>95%across subgroups of interest.The integrated safety analysis included 4,015 patients.Findings showed that 64.1%of patients reported an adverse event,and<0.1%of patients reported a serious adverse event related to glecaprevir/pibrentasvir.Conclusions:These results indicate that the 8-or 12-week glecaprevir/pibrentasvir treatment is effective for patients infected with HCV genotypes 1-6 without or with compensated cirrhosis,with good safety profiles,irrespective of treatment-experience.Glecaprevir/pibrentasvir is a good option for patients with human immunodeficiency virus/HCV coinfection and comorbid HCV and severe renal impairment.
基金
sponsored by the National Natural Science Foundation of China(Grant Nos.81972265,81700534)
the National Key Research Plan“Precision Medicine Research”Key Project(2017YFC0908103,2017YFC0908104,2018ZX10302206)
the National Science and Technology Major Project(2017ZX10202202)
the JLU Norman Bethune Research Plan(2018B32)
the Program for JLU Science and Technology Innovative Research Team(2017TD-08)
the Fundamental Research Funds for the Central Universities.
作者简介
Corresponding author:Yan-Hang Gao,Department of Hepatology,The First Hospital of Jilin University,Jilin University,No.71,Xinmin Street,Changchun,Jilin 130021,China.Tel:+86-431-81875121,E-mail:yanhang@mail.jlu.edu.cn
